BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been given a consensus recommendation of “Hold” by the twenty-seven research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $110.20.

Several brokerages recently weighed in on BMRN. UBS reiterated a “neutral” rating and issued a $93.00 price objective (up from $92.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, August 3rd. Deutsche Bank reiterated a “buy” rating and issued a $119.00 price objective (up from $118.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, August 3rd. Cowen reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Friday, August 4th. Stifel Nicolaus reiterated a “buy” rating and issued a $107.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, August 4th. Finally, Wedbush reiterated a “neutral” rating and issued a $108.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday, August 7th.

BioMarin Pharmaceutical (BMRN) traded down $0.80 during mid-day trading on Friday, hitting $85.00. The stock had a trading volume of 1,068,421 shares, compared to its average volume of 1,227,485. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical has a 1-year low of $79.50 and a 1-year high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $334.18 million during the quarter, compared to analyst estimates of $347.38 million. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The business’s revenue was up 19.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.02 earnings per share. equities research analysts predict that BioMarin Pharmaceutical will post -0.65 EPS for the current fiscal year.

In other news, EVP Jeffrey Robert Ajer sold 3,521 shares of the stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $95.00, for a total value of $334,495.00. Following the sale, the executive vice president now directly owns 49,299 shares in the company, valued at $4,683,405. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Robert Baffi sold 18,415 shares of the stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $92.43, for a total value of $1,702,098.45. Following the completion of the sale, the executive vice president now owns 129,083 shares in the company, valued at $11,931,141.69. The disclosure for this sale can be found here. Insiders have sold 40,686 shares of company stock worth $3,736,318 over the last 90 days. 1.85% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in BMRN. Jennison Associates LLC raised its stake in shares of BioMarin Pharmaceutical by 33.8% in the second quarter. Jennison Associates LLC now owns 13,242,773 shares of the biotechnology company’s stock valued at $1,202,709,000 after acquiring an additional 3,348,168 shares in the last quarter. TIAA CREF Investment Management LLC raised its stake in shares of BioMarin Pharmaceutical by 63.7% in the second quarter. TIAA CREF Investment Management LLC now owns 2,251,011 shares of the biotechnology company’s stock valued at $204,437,000 after acquiring an additional 875,686 shares in the last quarter. USS Investment Management Ltd raised its stake in shares of BioMarin Pharmaceutical by 214.7% in the second quarter. USS Investment Management Ltd now owns 1,089,933 shares of the biotechnology company’s stock valued at $98,988,000 after acquiring an additional 743,599 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of BioMarin Pharmaceutical by 4.7% in the second quarter. Vanguard Group Inc. now owns 14,345,027 shares of the biotechnology company’s stock valued at $1,302,816,000 after acquiring an additional 642,623 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 41.7% in the second quarter. Teachers Advisors LLC now owns 973,291 shares of the biotechnology company’s stock valued at $88,394,000 after acquiring an additional 286,249 shares in the last quarter. Institutional investors and hedge funds own 99.31% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BioMarin Pharmaceutical Inc. (BMRN) Receives Consensus Recommendation of “Hold” from Analysts” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/01/biomarin-pharmaceutical-inc-bmrn-receives-consensus-recommendation-of-hold-from-analysts.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.